Morgan Stanley Raises Price Target for Alnylam Pharmaceuticals
On July 10, 2026, Morgan Stanley raised its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) to $400 from $370 while maintaining an Equal Weight rating. This follows a similar move by Raymond James on July 9, which increased the firm's price target to $468 and kept an Outperform rating.
Topics: Biotech Pharmaceuticals Stock Analysis